Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611417 | 0.85 | CYP3A4 (0.47) | HTR2CHTR2ATSHRCYP3A4MAPT | |
| SCHEMBL6092803 | 0.75 | TSHR (0.57) | TSHRPOLBCYP3A4MAPT | |
| SCHEMBL9778659 | 0.73 | L3MBTL1 (0.47) | HTR2CHTR2ATSHRL3MBTL1 | |
| SCHEMBL9778610 | 0.72 | CA12 (0.46) | TSHRMAPTNPSR1 | |
| SCHEMBL9778646 | 0.72 | MEN1 (0.51) | TSHRTP53CYP3A4MAPTNPSR1 | |
| SCHEMBL11609976 | 0.72 | ACHE (0.46) | TSHRPOLBL3MBTL1TP53CYP3A4 | |
| SCHEMBL30669513 | 0.71 | TSHR (0.67) | TSHRNPSR1 | |
| SCHEMBL8057984 | 0.71 | TSHR (0.67) | TSHRNPSR1 | |
| SCHEMBL9262929 | 0.69 | TSHR (0.55) | TSHRCYP3A4MAPT | |
| SCHEMBL29654713 | 0.69 | HTR2C (0.45) | HTR2CHTR2APRKDCPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357584-A1 | ARYL NAPHTHALIDE LIGNANS AS ANTI-HIV AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357584-A1 | ARYL NAPHTHALIDE LIGNANS AS ANTI-HIV AGENTS | ALG8, GRAMD1A, LSS | HTR2C 660/4885HTR2A 624/4885TSHR 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.